EQT生命科学公司将通过向吉利德科学公司出售其在Tubulis的少数股权，以高达50亿美元的价格退出-动脉网

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

PR Newswire 等信源发布 2026-04-07 22:30



可切换为仅中文







Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company

吉利德科学公司已达成最终协议，将收购总部位于德国的私营临床阶段生物技术公司Tubulis。

EQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth to a leading global clinical-stage ADC company

EQT生命科学公司在2024年3月领投了Tubulis的B2轮融资，并在此后在董事会层面支持公司成长为全球领先的临床阶段ADC公司。

AMSTERDAM

阿姆斯特丹

，

April 7, 2026

2026年4月7日

/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund ('EQT Life Sciences') has exited its minority stake in Tubulis (the 'Company'), a Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: .

/PRNewswire/ -- EQT生命科学公司欣然宣布，LSP 7基金（“EQT生命科学”）已通过将其在Tubulis（“公司”）的少数股权出售给Gilead Sciences [纳斯达克：]的方式退出。Tubulis是一家总部位于德国的临床阶段生物技术公司，专注于开发下一代抗体药物偶联物（ADCs）。

GILD

吉利德科学公司

Tubulis' lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various solid tumor types as well as a next-generation ADC platform and a promising early pipeline..

Tubulis的主导资产TUB-040是一种针对NaPi2b的拓扑异构酶-I抑制剂（TOPO1i）ADC，目前正处于铂耐药卵巢癌和非小细胞肺癌（NSCLC）的1b/2期开发阶段。Gilead还将获得TUB-030，一种靶向5T4的ADC，该药物已在多种实体瘤类型中展现出良好的初步临床数据，同时还将获得一个下一代ADC平台和前景广阔的早期研发管线。

EQT Life Sciences co-led the oversubscribed Series B2 financing in 2024, and since then, has helped Tubulis advance into a clinical-stage oncology player, progress its pipeline, and build a differentiated antibody-drug conjugate platform targeting solid tumors. Working closely with the management team, EQT Life Sciences supported this journey through active board involvement and strategic guidance, helping position Tubulis as a partner of choice in a rapidly growing and highly competitive field..

EQT生命科学公司在2024年共同领投了超额认购的B2轮融资，并自此帮助Tubulis发展成为一家临床阶段的肿瘤学公司，推进其研发管线，并打造了一个针对实体瘤的差异化抗体药物偶联平台。通过与管理团队密切合作，EQT生命科学公司通过积极的董事会参与和战略指导支持了这一进程，助力Tubulis在快速增长且高度竞争的领域中成为首选合作伙伴。

The transaction represents a strong and strategic outcome for LSP 7 and its co-investors, and reflects EQT Life Sciences' ambition to back outstanding science early, helping companies scale through critical inflection points into globally relevant businesses. Today's announcement also underscores the continued demand for innovative oncology platforms that can address significant unmet medical needs..

该交易对LSP 7及其共同投资者而言是一个强有力且具有战略意义的成果，反映了EQT生命科学公司早期支持杰出科学的决心，帮助公司在关键转折点扩大规模，成为具有全球相关性的企业。今天的公告还强调了市场对于能够满足重大未满足医疗需求的创新肿瘤学平台的持续需求。

'From the outset, we believed our conjugation technology platforms could have broad impact across the ADC field, and the initial data from TUB-040 have reinforced that conviction,' said Dominik Schumacher, PhD, Chief Executive Officer and Co-founder of Tubulis. 'Joining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide.

“从一开始，我们就相信我们的偶联技术平台可以对ADC领域产生广泛影响，而TUB-040的初步数据进一步坚定了我们的信念，”Tubulis首席执行官兼联合创始人Dominik Schumacher博士表示，“加入Gilead使我们能够在一家拥有深厚科学专业知识、全球开发能力以及将创新转化为惠及全球患者药物所需规模的组织中，继续在此基础上发展。”

Through our existing collaboration, Gilead has already seen the potential of our technologies and together, we are well positioned to accelerate the development of our ADC pipeline. I'm deeply grateful to the Tubulis team, our Board of Directors, investors, and partners for their commitment and helping make this milestone possible.'.

通过我们现有的合作，Gilead已经看到了我们技术的潜力，同时，我们也有能力加速推进我们的ADC管线开发。我衷心感谢Tubulis团队、董事会、投资者以及合作伙伴们的投入与支持，帮助实现了这一里程碑。

'From day one, it was clear that Tubulis had both the science and the ambition to compete at the very highest level in oncology,' said Christoph Broja, Partner at EQT Life Sciences and Board Director at Tubulis.' A European-born platform with world-class talent and technology, this is exactly the kind of company EQT Life Sciences was built to back.

“从第一天起，Tubulis就展现了在肿瘤学领域最高水平竞争的科学实力和雄心壮志，”EQT生命科学合伙人兼Tubulis董事会成员克里斯托夫·布罗亚表示。“这个诞生于欧洲的平台拥有世界级的人才和技术，正是EQT生命科学旨在支持的公司类型。”

Today's announcement is a testament to that conviction, and we are proud to have supported its journey from Munich to the global stage'.

今天的公告证明了这一信念，我们很自豪能够支持它从慕尼黑走向全球舞台。

Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs.

交易完成后，Tubulis 将作为一家专注于 ADC 研究的组织在吉利德内部运营，其慕尼黑基地将成为 ADC 创新的中心，依托其整合的研发、生产和临床能力，推动下一代 ADC 的发展。

Terms of the Transaction

交易条款

Under the terms of the sale and purchase agreement, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments.

根据买卖协议的条款，吉利德将收购Tubulis所有已发行股权，初始现金对价为31.5亿美元，基于无现金、无债务的基础，并需进行惯例调整，该款项将在交割时支付，此外还有可能支付高达18.5亿美元的或有里程碑付款。

Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. The transaction is expected to close in the second quarter of 2026. Gilead plans to finance the transaction with a combination of cash on hand and senior unsecured notes..

交易的完成取决于某些监管文件的到期或终止以及其他惯例条件。该交易预计将于2026年第二季度完成。吉利德计划通过手中现金和高级无担保票据相结合的方式来为本次交易融资。

Centerview Partners LLC and Allen & Company LLC are acting as financial advisors for Gilead. J.P. Morgan Securities LLC is acting as the exclusive financial advisor for Tubulis. Covington & Burling LLP, Arnold & Porter LLP, and Venable LLP are serving as legal counsel to Gilead. Goodwin Procter LLP and CMS Hasche Sigle are serving as legal counsel to Tubulis..

Centerview Partners LLC 和 Allen & Company LLC 担任吉利德的财务顾问。J.P. Morgan Securities LLC 担任 Tubulis 的独家财务顾问。Covington & Burling LLP、Arnold & Porter LLP 和 Venable LLP 担任吉利德的法律顾问。Goodwin Procter LLP 和 CMS Hasche Sigle 担任 Tubulis 的法律顾问。

EQT Contact

EQT 联系方式

EQT Press Office,

EQT新闻办公室，

[email protected]

电子邮件地址

Tubulis Contact

Tubulis 联系方式

Stephanie May, PhD,

斯蒂芬妮·梅，博士，

[email protected]

电子邮件地址